Compare General Motors Company (GM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Novo Nordisk A/S — how do they compare? General Motors Company trades at $82.35 (market cap $72.17B), while Novo Nordisk A/S trades at $38.43 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.3× General Motors Company's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Novo Nordisk A/S for 116 Days on average.
| GM | NVO | |
|---|---|---|
Market Cap | $72.17B | $165.31B |
Volume | 4,900,304 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $63.98 |
52-Week Low | $55.35 | $35.29 |
Typical Hold Time | 83 Days | 116 Days |
Enterprise Value | $175.15B | $179.56B |
Dividend Yield | 0.88% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.34, up 1.67% with recent earnings beats but faces bearish technical signals. The company reported declining Q3 2026 vehicle sales of 5.5% amid EV market challenges, while maintaining strong cash flow from operations at $26.87B in 2025. Valuation metrics show a P/E of 36.72 and P/S of 0.42, with analyst consensus favoring a Buy rating and $102.08 price target.
GM's outlook is mixed with solid fundamentals offset by near-term headwinds. Investment opportunities include potential regulatory savings of $20.4B from eased fuel economy rules and consistent earnings outperformance. Key risks involve competitive pressure from Asian automakers, declining market share, and profitability pressures with net margins at 1.05%.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
